Post-earnings recap
Reported
Fri, Jul 31, 2026
EPS actual
$1.49
EPS est.
$1.40
EPS surprise
+6.81%
1-day move
+2.97%
Balchem Corporation reported better-than-expected earnings per share, which likely contributed to the stock's increase of nearly 3%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors may view the EPS beat positively, but the lack of revenue information could lead to cautious sentiment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.49 | $1.43 | +6.81% |
| Revenue | N/A | $269M | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Balchem Corporation (BCPC) operates in the specialty chemicals sector, focusing on innovative solutions for food, nutrition, and health. With a market cap of $6 billion, the company plays a crucial role in supplying essential ingredients that cater to various industries, including food production and pharmaceuticals.
Last quarter
In Q1-2026, Balchem reported an EPS of $1.33, matching analyst expectations, but the stock fell by 6.76% the following day. The company did not provide revenue figures, leaving investors uncertain about sales performance.
EPS beat streak
1Q
EPS beat rate
63%
Avg EPS surprise
+2.40%
Avg 1-day reaction
+0.06%
Analysts expect Balchem to report stable earnings and revenue figures this quarter, with a consensus EPS of $1.43 and revenue of $269 million. Investors are closely watching for any signs of growth or challenges in demand.
Bull case
If Balchem exceeds EPS expectations and shows strong revenue growth, it could indicate robust demand for its products, leading to positive investor sentiment.
Bear case
Conversely, if the company misses earnings or revenue estimates, it may signal underlying issues in sales or market conditions, potentially leading to a decline in stock price.
Key metrics to watch
EPS
$1.43Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$269MTotal revenue reflects the overall sales performance and demand for Balchem's products, which is critical for assessing growth.
The print will turn on these.
Q1
Will Balchem achieve an EPS of $1.43 or higher?
This specific EPS target is crucial as it will indicate whether the company is effectively managing its costs and driving profitability.
Q2
What will be the revenue figure compared to the $269 million consensus?
Revenue performance is key to understanding market demand and growth potential, and any significant deviation could impact investor confidence.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±1.6%
Why consensus could be wrong
The consensus may underestimate the potential for Balchem to exceed revenue expectations due to recent trends in demand for specialty chemicals, which have been stronger than anticipated.
Supporting evidence
Balchem has a history of beating EPS estimates 75% of the time, indicating a potential for positive surprises.
The options market is pricing in a larger move than historical averages, suggesting that traders expect significant volatility.
Recent industry trends show increased demand for specialty chemicals, which could benefit Balchem.
Key risk
If revenue comes in below $260 million, it could challenge the positive outlook and lead to a reassessment of growth prospects.
Pre-commit to what would confirm each case.
This quarter's results will heavily influence perceptions of Balchem's growth trajectory and market stability.
Bull confirmed if
An EPS of $1.45 or higher, coupled with revenue exceeding $270 million, would confirm strong operational performance.
Bear confirmed if
An EPS below $1.40 and revenue under $267 million would suggest potential challenges in demand and profitability.
What the market is pricing for the move.
Implied Move
±10.08%
Historical Avg
±2.9%
The options market is pricing in a significant move of about 10% in either direction, suggesting that traders expect volatility around the earnings report.
Options are pricing ±10.1% while BCPC has averaged ±2.9% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
25.3%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Materials
Fade rate: 14 of 30 (47%)
This setup has occurred 30 times across Materials in the last 2 years. 14 of 30 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.5%, with a raw directional average of +0.3% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
93.79%
of float
Insider
0.49%
of float
Holders
560
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
4,964,479 sh · $826.1M
15.57%
2.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Balchem beats expectations, history suggests the stock could see a modest uptick, confirming positive market sentiment.
In line / cautious
If results come in line with expectations, the stock may experience limited movement as investors await further guidance.
Miss
Should the company miss estimates, history indicates a potential decline in stock price, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Portfolio Management LLC
2,221,267 sh · $369.6M
6.97%
1.3%
Vanguard Capital Management LLC
1,445,369 sh · $240.5M
4.53%
0.9%
State Street Corporation
1,281,552 sh · $213.3M
4.02%
3.3%
Geode Capital Management, LLC
1,122,146 sh · $186.7M
3.52%
7.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Jul 10, 2026 · disclosed Sep 4, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.